Etern Therapeutics
ETERN was established in 2018, focusing on the research and development of small molecule drugs targeting protein liquid-liquid phase separation. The LLPS platform, the state-of-art protein liquid-liquid phase separation platform developed by Etern, integrate cutting edge techniques including protein phase separation biology, AI-based target identification and verification, phase separation-based phenotypic screening, image recognition-based hit finding, etc. The platform provides a novel strategy for drug R&D, especially for “undruggable"targets.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
7
11 to 50 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
2
organic / mo
Sign up free to see all 5 verified contacts at Etern Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Etern Therapeutics
5 distinct titles indexed · top 5 shown.
- 1co-founder and ceo
- 1director clinical operations
- 1head of chemistry
- 1head of preclinical development
- 1vice president of business development
Sign up to unlock all 5 contacts at Etern Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Etern Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.